234 related articles for article (PubMed ID: 21129096)
1. A meta-analysis of randomized controlled trials comparing chemotherapy plus trastuzumab with chemotherapy alone in HER-2-positive advanced breast cancer.
Liao C; Yin F; Huang P; Cao Y; Gao F
Breast J; 2011; 17(1):109-11. PubMed ID: 21129096
[No Abstract] [Full Text] [Related]
2. Adjuvant trastuzumab: a milestone in the treatment of HER-2-positive early breast cancer.
Baselga J; Perez EA; Pienkowski T; Bell R
Oncologist; 2006; 11 Suppl 1():4-12. PubMed ID: 16971734
[TBL] [Abstract][Full Text] [Related]
3. Trastuzumab faces trials, clinical and otherwise.
Tuma RS
J Natl Cancer Inst; 2006 Mar; 98(5):296-8. PubMed ID: 16507822
[No Abstract] [Full Text] [Related]
4. Trastuzumab trials steal show at ASCO meeting.
Tuma RS
J Natl Cancer Inst; 2005 Jun; 97(12):870-1. PubMed ID: 15956644
[No Abstract] [Full Text] [Related]
5. [Breast cancer: adjuvant therapy with trastuzumab: herceptin adjuvant (HERA) Trial Study, B-31- and N9831-Study].
Mallmann P
Internist (Berl); 2006 Nov; 47(11):1183-5. PubMed ID: 17048017
[No Abstract] [Full Text] [Related]
6. [A meta-analysis of neoadjuvant chemotherapy combined with trastuzumab for HER2-positive breast cancers].
Liao N; Zhang GC; Li XR; Yao M; Wang K
Nan Fang Yi Ke Da Xue Xue Bao; 2009 May; 29(5):943-5. PubMed ID: 19460715
[TBL] [Abstract][Full Text] [Related]
7. Lapatinib moves forward in inflammatory and early HER2-positive breast cancer trials.
Tuma RS
J Natl Cancer Inst; 2007 Mar; 99(5):348-9. PubMed ID: 17341725
[No Abstract] [Full Text] [Related]
8. Herceptin produces clinical benefit in metastatic breast cancer regardless of tumor response.
Oncology (Williston Park); 2004 Aug; 18(9):1201. PubMed ID: 15471203
[No Abstract] [Full Text] [Related]
9. Herceptin (trastuzumab): adjuvant and neoadjuvant trials.
Yaal-Hahoshen N; Safra T
Isr Med Assoc J; 2006 Jun; 8(6):416-21. PubMed ID: 16833172
[No Abstract] [Full Text] [Related]
10. [Medical, non-endocrine treatment of metastatic breast cancer--a status].
Lindberg H; Nielsen DL; Kamby C
Ugeskr Laeger; 2007 Apr; 169(17):1556-60. PubMed ID: 17484824
[TBL] [Abstract][Full Text] [Related]
11. Trastuzumab: targeted therapy for the management of HER-2/neu-overexpressing metastatic breast cancer.
Emens LA
Am J Ther; 2005; 12(3):243-53. PubMed ID: 15891269
[TBL] [Abstract][Full Text] [Related]
12. [Human recombinant anti-HER2 monoclonal antibody--a new targeted treatment in breast cancer].
Dank M
Orv Hetil; 2001 Nov; 142(46):2563-8. PubMed ID: 11770175
[TBL] [Abstract][Full Text] [Related]
13. Refining therapy for human epidermal growth factor receptor 2-positive breast cancer: T stands for trastuzumab, tumor size, and treatment strategy.
Burstein HJ; Winer EP
J Clin Oncol; 2009 Dec; 27(34):5671-3. PubMed ID: 19884535
[No Abstract] [Full Text] [Related]
14. HER-2-targeted therapy: lessons learned and future directions.
Nahta R; Esteva FJ
Clin Cancer Res; 2003 Nov; 9(14):5078-84. PubMed ID: 14613984
[TBL] [Abstract][Full Text] [Related]
15. Trastuzumab plus chemotherapy improves survival in early-stage HER2-positive breast cancer patients.
Oncology (Williston Park); 2005 Jun; 19(7):851, 862. PubMed ID: 16053034
[No Abstract] [Full Text] [Related]
16. Surgery following neoadjuvant therapy in patients with HER2-positive locally advanced or inflammatory breast cancer participating in the NeOAdjuvant Herceptin (NOAH) study.
Semiglazov V; Eiermann W; Zambetti M; Manikhas A; Bozhok A; Lluch A; Tjulandin S; Sabadell MD; Caballero A; Valagussa P; Baselga J; Gianni L
Eur J Surg Oncol; 2011 Oct; 37(10):856-63. PubMed ID: 21843921
[TBL] [Abstract][Full Text] [Related]
17. Adjuvant trastuzumab for HER2-positive early breast cancer.
Palmieri FM; Myatt CV; Perez EA
Clin J Oncol Nurs; 2010 Jun; 14(3):326-36. PubMed ID: 20529794
[TBL] [Abstract][Full Text] [Related]
18. Trastuzumab, a recombinant DNA-derived humanized monoclonal antibody, a novel agent for the treatment of metastatic breast cancer.
Goldenberg MM
Clin Ther; 1999 Feb; 21(2):309-18. PubMed ID: 10211534
[TBL] [Abstract][Full Text] [Related]
19. [Potential risk and benefit of the combination of trastuzumab to chemotherapy and radiation therapy in non-metastatic breast cancer].
Belkacémi Y; Laharie-Mineur H; Gligorov J; Azria D
Cancer Radiother; 2007 Sep; 11(5):266-75. PubMed ID: 17644449
[TBL] [Abstract][Full Text] [Related]
20. [The requirements to clinicopathology about targeted therapy for breast cancer].
Jiang ZF; Shen G
Zhonghua Bing Li Xue Za Zhi; 2007 Jul; 36(7):435-7. PubMed ID: 17845752
[No Abstract] [Full Text] [Related]
[Next] [New Search]